Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...

A cell therapy developer with operations at the Philadelphia Navy Yard plans reduce its headcount by 33% next year as it ...

The primary analysis includes 64 patients with previously treated, advanced synovial sarcoma or myxoid/round cell liposarcoma ...

要问当代人什么时候最惆怅，我想，应该是去医院做检查的时候吧？对于很多人来说，“医院就诊”，是一件不亚于坐过山车、玩密室般胆战心惊的事情，检测单上一路绿灯，心里的大石头才能放下，可一旦有个“特别”症状，心里就好像添了一块大石头，饭都吃不香了。

MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses ...

Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Aggressive angiomyxoma (AA) of the vulva is a rare, benign, slow-growing tumour that arises from the myxoid cells of the connective tissue. It has a low tendency to metastasise, but a high chance of ...

myxoid pattern) of the neoplastic cells. Because the pattern may be lacking, different features may be seen in different areas of the same tumor and similar patterns may also be found in some ...

Medical students should consider how AI could change the work physicians do (and get paid for) when choosing specialties.

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...